

Membrane proteins and joint hypermobility syndrome: A thorough review

Raquel Carrow*

Department of Biochemical Engineering, Tecnológico Nacional de México in Celaya, Guanajuato, Mexico

INTRODUCTION

Joint Hypermobility Syndrome (JHS) is a complex connective tissue disorder characterized by excessive joint mobility and a variety of associated symptoms, including joint pain, fatigue, and musculoskeletal issues. While the etiology of JHS remains multifactorial and not fully understood, emerging research has suggested a potential link between membrane proteins and the pathogenesis of this syndrome. Membrane proteins play crucial roles in cell signaling, transport, and structural integrity, making them intriguing candidates for exploring the molecular mechanisms underlying JHS. This comprehensive review aims to elucidate the current understanding of membrane proteins in the context of JHS, examining their roles, interactions, and potential implications for diagnosis and treatment.

Membrane proteins are essential components of cellular membranes, playing critical roles in various physiological processes. Joint Hypermobility Syndrome (JHS) is a connective tissue disorder characterized by excessive joint mobility and associated symptoms. Despite being seemingly disparate subjects, recent research suggests a potential link between membrane proteins and JHS. This comprehensive review aims to delve into the intricate relationship between membrane proteins and JHS, exploring their roles, interactions, and implications. Cell membranes serve as barriers separating the cell from its environment, regulating the passage of ions, molecules, and signals. Membrane proteins are integral to these functions, mediating diverse cellular processes such as signal transduction, transport, and adhesion. Membrane proteins are classified into two main categories based on their association with the lipid bilayer: integral and peripheral. Integral membrane proteins traverse the lipid bilayer, while peripheral membrane proteins are bound to the membrane surface.

Integral membrane proteins exhibit diverse structures, including alpha-helical bundles, beta-barrels, and combinations thereof. These structural motifs determine the protein's function and interactions within the membrane environment. Membrane proteins fulfill a myriad of functions crucial for cellular homeostasis and signaling. These include ion channels, receptors, transporters, and enzymes, each playing specialized roles in cellular physiology.

DESCRIPTION

JHS is a heritable connective tissue disorder characterized by joint laxity, chronic pain, and musculoskeletal

Address for correspondence:

Raquel Carrow
Department of Biochemical Engineering, Tecnológico Nacional de México in Celaya, Guanajuato, Mexico
E-mail: rcarrow3@gmail.com

Word count: 705 **Tables:** 00 **Figures:** 00 **References:** 05

Received: 01.02.2024, Manuscript No. ipjnn-24-14843; **Editor assigned:** 03.02.2024, PreQC No. P-14843; **Reviewed:** 14.02.2024, QC No. Q-14843; **Revised:** 21.02.2024, Manuscript No. R-14843; **Published:** 27.02.2024

symptoms. While the exact etiology remains unclear, genetic factors, collagen abnormalities, and alterations in connective tissue integrity are implicated. Individuals with JHS often exhibit generalized joint hypermobility, skin hyperextensibility, and musculoskeletal symptoms such as joint pain, instability, and fatigue. Extra-articular manifestations may include autonomic dysfunction, gastrointestinal symptoms, and anxiety disorders.

The underlying pathophysiology of JHS involves aberrations in collagen synthesis, structure, or processing, leading to compromised connective tissue integrity. Genetic mutations affecting collagen and related proteins contribute to the phenotypic expression of JHS. Emerging evidence suggests a potential association between membrane proteins and the pathogenesis of JHS. Several hypotheses propose mechanisms through which membrane proteins may influence connective tissue homeostasis and contribute to JHS phenotypes.

Ion channels are integral membrane proteins that regulate ion flux across cell membranes, influencing cellular excitability and signaling pathways. Dysregulation of ion channels may perturb intracellular calcium dynamics, impacting collagen synthesis, and extracellular matrix remodeling, thereby contributing to connective tissue abnormalities observed in JHS. Cell Adhesion Molecules (CAMs) play crucial roles in cell-cell and cell-matrix interactions, modulating tissue integrity and remodeling. Aberrant expression or function of CAMs may disrupt connective tissue architecture, predisposing individuals to joint laxity and hypermobility characteristic of JHS.

Membrane transporters regulate the influx and efflux of metabolites, nutrients, and signaling molecules, influencing cellular metabolism and homeostasis.

Dysfunctional transporters may alter nutrient availability, energy metabolism, and extracellular matrix synthesis, contributing to the pathophysiology of JHS. Genetic studies have identified potential candidate genes encoding membrane proteins implicated in JHS susceptibility. Variants in genes encoding ion channels, transporters, and cell adhesion molecules have been associated with connective tissue disorders, highlighting the genetic heterogeneity underlying JHS [1-5].

CONCLUSION

Understanding the interplay between membrane proteins and JHS holds promise for developing targeted therapeutic interventions. Strategies aimed at modulating ion channel activity, restoring extracellular matrix integrity, or targeting downstream signaling pathways may offer novel avenues for managing JHS symptoms and improving patient outcomes. In conclusion, membrane proteins play integral roles in cellular physiology and may contribute to the pathogenesis of joint hypermobility syndrome. Further research is warranted to elucidate the mechanistic links between membrane proteins and JHS, paving the way for innovative therapeutic strategies and personalized management approaches. By unraveling the complex interplay between membrane proteins and JHS, we can advance our understanding of connective tissue disorders and improve patient care in clinical practice.

ACKNOWLEDGEMENT

None.

CONFLICT OF INTEREST

None.

REFERENCES

- Ritelli M, Chiarelli N, Cinquina V, Vezzoli M and Venturini M, et al. Looking back and beyond the 2017 diagnostic criteria for hypermobile ehlers-danlos syndrome: A retrospective cross-sectional study from an Italian reference center. *Am J Med Genet A*. 2024; 194(2):174-194.
- Ritelli M, Chiarelli N, Cinquina V, Zoppi N and Bertini V, et al. RNA-seq of dermal fibroblasts from patients with hypermobile ehlers-danlos syndrome and hypermobility spectrum disorders supports their categorization as a single entity with involvement of extracellular matrix degrading and proinflammatory pathomechanisms. *Cells*. 2022; 11(24):4040.
- Cattalini M, Khubchandani R, Cimaz R. When flexibility is not necessarily a virtue: A review of hypermobility syndromes and chronic or recurrent musculoskeletal pain in children. *Pediatr Rheumatol*. 2015 Dec; 13:1-9.
- Carroll MB. Hypermobility spectrum disorders: A review. *Rheumatol Immunol Res*. 2023; 4(2):60-68.
- Tofts LJ, Elliott EJ, Munns C, Pacey V and Sillence DO. The differential diagnosis of children with joint hypermobility: A review of the literature. *Pediatr Rheumatol*. 2009; 7:1-10.